<qa>  What is the standard of care brimonidine topical gel?An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel 0.33 with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine. Before starting treatment, subjects will be reminded that brimonidine is indicated for persistent, not transient, erythema. Subjects will be given a copy of the product package insert and a copy of the American Academy of Dermatology website information on rosacea that contains standardized information about the diagnosis and triggers. 